Oak Thistle LLC Has $808,000 Stock Position in STERIS plc $STE

Oak Thistle LLC lessened its position in STERIS plc (NYSE:STE) by 80.3% in the third quarter, according to its most recent disclosure with the SEC. The firm owned 3,266 shares of the medical equipment provider’s stock after selling 13,343 shares during the period. Oak Thistle LLC’s holdings in STERIS were worth $808,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently modified their holdings of STE. Mediolanum International Funds Ltd lifted its stake in shares of STERIS by 9.0% in the second quarter. Mediolanum International Funds Ltd now owns 62,327 shares of the medical equipment provider’s stock valued at $14,883,000 after buying an additional 5,156 shares in the last quarter. Entropy Technologies LP raised its holdings in shares of STERIS by 282.2% in the 2nd quarter. Entropy Technologies LP now owns 9,099 shares of the medical equipment provider’s stock worth $2,186,000 after acquiring an additional 6,718 shares during the last quarter. Vanguard Group Inc. lifted its position in STERIS by 1.7% in the 2nd quarter. Vanguard Group Inc. now owns 12,163,128 shares of the medical equipment provider’s stock valued at $2,921,827,000 after acquiring an additional 205,276 shares in the last quarter. Foresight Group Ltd Liability Partnership acquired a new position in STERIS during the 1st quarter valued at about $25,958,000. Finally, KLP Kapitalforvaltning AS increased its holdings in STERIS by 5.3% during the 2nd quarter. KLP Kapitalforvaltning AS now owns 33,800 shares of the medical equipment provider’s stock worth $8,119,000 after purchasing an additional 1,700 shares in the last quarter. 94.69% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on STE shares. Weiss Ratings reiterated a “buy (b)” rating on shares of STERIS in a report on Tuesday, October 14th. Wall Street Zen raised shares of STERIS from a “buy” rating to a “strong-buy” rating in a report on Sunday, September 14th. Seven equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $273.50.

STERIS Stock Performance

Shares of STERIS stock opened at $251.54 on Friday. The business’s fifty day simple moving average is $252.19 and its 200 day simple moving average is $244.05. The company has a current ratio of 2.37, a quick ratio of 1.63 and a debt-to-equity ratio of 0.27. STERIS plc has a 12 month low of $200.98 and a 12 month high of $268.60. The firm has a market capitalization of $24.69 billion, a P/E ratio of 36.14 and a beta of 1.01.

STERIS (NYSE:STE) last announced its earnings results on Wednesday, November 5th. The medical equipment provider reported $2.47 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.38 by $0.09. The firm had revenue of $1.46 billion during the quarter, compared to analyst estimates of $1.43 billion. STERIS had a return on equity of 14.43% and a net margin of 12.07%.During the same period last year, the firm posted $2.14 EPS. STERIS has set its FY 2026 guidance at 10.150-10.30 EPS. As a group, analysts anticipate that STERIS plc will post 9.08 EPS for the current year.

STERIS Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, December 18th. Shareholders of record on Tuesday, November 18th were given a $0.63 dividend. The ex-dividend date of this dividend was Tuesday, November 18th. This represents a $2.52 annualized dividend and a yield of 1.0%. STERIS’s payout ratio is currently 36.21%.

Insider Activity at STERIS

In other news, VP Renato Tamaro sold 5,036 shares of the stock in a transaction that occurred on Tuesday, November 18th. The shares were sold at an average price of $257.55, for a total transaction of $1,297,021.80. Following the completion of the transaction, the vice president directly owned 5,695 shares of the company’s stock, valued at $1,466,747.25. This represents a 46.93% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Daniel A. Carestio sold 159 shares of the firm’s stock in a transaction that occurred on Monday, October 6th. The stock was sold at an average price of $241.82, for a total transaction of $38,449.38. Following the sale, the chief executive officer owned 51,096 shares of the company’s stock, valued at approximately $12,356,034.72. The trade was a 0.31% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 25,203 shares of company stock valued at $6,624,667 in the last three months. Insiders own 1.07% of the company’s stock.

STERIS Profile

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.